fenretinide lipid matrix

DRUG2 trials

Sponsors

New Approaches to Neuroblastoma Therapy Consortium, National Institutes of Health Clinical Center (CC)

Conditions

LymphomaNeuroblastomaUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

CompletedNCT00295919

New Approaches to Neuroblastoma Therapy ConsortiumNeuroblastoma

Start: 2005-12-01End: 2015-05-01Updated: 2026-04-14

Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma

CompletedNCT00589381

National Institutes of Health Clinical Center (CC)Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2007-08-31End: 2011-03-31Target: 30Updated: 2012-03-08

Related Papers

Fenretinide (4-HPR)/Lym-X-Sorb (LXS) oral powder plus ketoconazole in patients with high-risk (HR) recurrent or resistant neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium trial.

Journal of Clinical Oncology2014-05-2010 citations